Prevencio Picks Up U.S., European, Japanese Patents for AI-Driven CAD Blood Test

Prevencio Inc. has been granted patents for its HART CADhs test in the United States—marking the second U.S. patent for this test—as well as the European Union and Japan. The patents protect Prevencio’s proprietary methods and algorithms for detecting obstructive coronary artery disease (CAD) using a multi-protein, artificial intelligence (AI)-driven blood test platform.

The newly issued patents strengthen Prevencio’s intellectual property portfolio and support its long-term strategy to expand HART CADhs adoption globally. HART CADhs is the only blood test that combines multiple cardiac proteins with machine learning to deliver a highly accurate, non-invasive diagnosis of obstructive CAD, according to the company.

“Securing patent protection in the U.S., Europe, and Japan marks a major step forward in advancing our innovation and market leadership,” Prevencio CEO Rhonda Rhyne said. “These patents reinforce the uniqueness of our HART CADhs test and underscore our commitment to improving cardiovascular diagnostics worldwide.”

With two marketed, AI-driven blood tests—HART CADhs and HART CVE—and bolstered by international patent protection, compelling clinical data, reimbursement, and recent U.S. Food and Drug Administration Breakthrough Device Designation, Prevencio delivers a convergence of innovation, validation, and commercial readiness.

“Cardiovascular disease is a global problem. International patent protection will help Prevencio to deliver scalable solutions that meet urgent diagnostic needs in the U.S. as well as global markets,” said James L. Januzzi, M.D., a practicing cardiologist at MGH, professor of Medicine at Harvard Medical School, chief scientific officer at the Baim Institute for Clinical Research, and principal investigator for the HART test development and validation.

Cardiovascular disease remains the leading cause of death worldwide and accounts for more than $318 billion in annual U.S. healthcare costs, nearly 10% of total healthcare spending. Prevencio’s HART blood tests are designed to improve accessibility, accuracy, and patient outcomes while reducing costs through earlier, more accessible, and accurate blood diagnostics.

Both HART CADhs and HART CVE—a second AI-driven, multi-protein blood test that assesses a patient’s one-year risk of heart attack, stroke, or cardiovascular death—are currently available to healthcare providers and for research use.

Prevencio is improving cardiovascular care through AI-driven blood tests that deliver earlier, accurate, and more accessible diagnostics. The company’s HART platform powers the development of proprietary tests for cardiovascular disease, including HART CADhs for detecting obstructive coronary artery disease and HART CVE for assessing one-year risk of heart attack, stroke, or cardiovascular death.